Barclays’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-54,219
| Closed | -$1.82M | – | 5604 |
|
|
2026
Q1 | $1.82M | Sell |
54,219
-103,466
| -66% | -$4.06M | ﹤0.01% | 2414 |
|
|
2025
Q4 | $7.3M | Sell |
157,685
-13,295
| -8% | -$729K | ﹤0.01% | 1928 |
|
|
2025
Q3 | $11.6M | Buy |
170,980
+32,565
| +24% | +$2.41M | ﹤0.01% | 1558 |
|
|
2025
Q2 | $11.6M | Buy |
138,415
+60,086
| +77% | +$4.5M | ﹤0.01% | 1473 |
|
|
2025
Q1 | $5.6M | Sell |
78,329
-48,346
| -38% | -$2.35M | ﹤0.01% | 1822 |
|
|
2024
Q4 | $5.69M | Buy |
126,675
+74,130
| +141% | +$3.84M | ﹤0.01% | 2032 |
|
|
2024
Q3 | $2.65M | Buy |
52,545
+31,467
| +149% | +$1.51M | ﹤0.01% | 2617 |
|
|
2024
Q2 | $860K | Buy |
21,078
+459
| +2% | +$19.5K | ﹤0.01% | 2687 |
|
|
2024
Q1 | $882K | Sell |
20,619
-686
| -3% | -$31K | ﹤0.01% | 3218 |
|
|
2023
Q4 | $858K | Buy |
+21,305
| New | +$606K | ﹤0.01% | 3555 |
|
|
2021
Q4 | – | Sell |
-455
| Closed | -$6K | – | 4682 |
|
|
2021
Q3 | $6K | Buy |
455
+16
| +4% | +$223 | ﹤0.01% | 4589 |
|
|
2021
Q2 | $8K | Sell |
439
-2,881
| -87% | -$48.7K | ﹤0.01% | 4696 |
|
|
2021
Q1 | $63K | Buy |
3,320
+2,038
| +159% | +$65.7K | ﹤0.01% | 4155 |
|
|
2020
Q4 | $37K | Sell |
1,282
-527
| -29% | -$15.2K | ﹤0.01% | 4534 |
|
|
2020
Q3 | $68K | Buy |
1,809
+590
| +48% | +$17.2K | ﹤0.01% | 4449 |
|
|
2020
Q2 | $40K | Buy |
+1,219
| New | +$52.8K | ﹤0.01% | 5020 |
|
Barclays's SLNO Position: Q2 2026 in Review
Barclays sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 54,219 shares — an estimated $1.82M sold.
Barclays first reported a position in SLNO in Q2 2020 and held it in 16 quarters. The position peaked at $11.6M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Barclays reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Barclays sold 54,219 Soleno Therapeutics shares in Q2 2026, an estimated $1.82M.
- Barclays first reported a position in Soleno Therapeutics in Q2 2020 and held it in 16 quarters.
- Barclays's Soleno Therapeutics position peaked at $11.6M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.